Sen. Richard Blumenthal: Should be some objective review of AI products before deployment

Summary

Sen. Richard Blumenthal discusses AI regulation on CNBC, arguing for FDA-like objective review before AI products are deployed. He highlights risks such as rogue bots and social-media harms while saying he wants to avoid slowing innovation or harming U.S. competitiveness. He mentions the bipartisan AI Risk Evaluation Act and China's own interest in regulating AI. He also criticizes Big Tech's lobbying against the Kids Online Safety Act.

• Blumenthal calls for pre-deployment review of AI products.
• He analogizes AI oversight to FDA review for drugs and medical devices.
• He warns of rogue bots, toxic algorithms, and monopolistic control.
• He says regulation should be international and not stifle innovation.
• He cites China's interest in regulating AI to protect its regime.
• He promotes the bipartisan AI Risk Evaluation Act.
• He says Big Tech lobbying stymied the Kids Online Safety Act in the House.